论文部分内容阅读
有些癌症患者能产生对抗p53肿瘤抑制蛋白的抗体。人们一直认为血清中出现的这种抗体系肿瘤p53突变的表达。某些研究也提示这种病人存活期更短。本研究的目标是确定抗p53抗体在新确诊的小细胞肺痛患者血清中出现的情况,评估这种抗体在血清中存在与临床的相关性,特别是对肿瘤治疗的反应和与患者存活情况的关系。取确诊的小细胞肺癌患者血清,患者为1991年10月至1994年6月在西班牙巴塞罗那4个医院准备接受铂制剂或阿霉素为主的化疗者。以血库献血者
Some cancer patients can produce antibodies against the p53 tumor suppressor protein. It has been thought that expression of this anti-system tumor p53 mutation occurs in serum. Some studies also suggest that this patient has a shorter survival period. The goal of this study was to determine the presence of anti-p53 antibodies in the serum of newly diagnosed patients with small cell lung pain, and to evaluate the presence of this antibody in serum and its clinical relevance, especially in response to tumor treatment and survival. Relationship. The serum of patients diagnosed with small cell lung cancer was taken from October 1991 to June 1994 in four hospitals in Barcelona, Spain, to receive platinum-based or doxorubicin-based chemotherapy. Blood bank donors